Trump Vows To Cut 'The Best Deal' On Drug Prices. What To Expect.
Imagine forking out north of $25,000 for a month's supply of the drug keeping you alive. That's what many hepatitis C patients in the U.S. have had to pay for a 28-day course of Gilead Sciences' (GILD) Epclusa. Canadians paid 35% less for the same treatment, while Australians could buy nearly three months of the drug for roughly the same price.
IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC.
Sent to: dupa@niepodam.pl
Investor's Business Daily, LLC, PO Box 300, Princeton, NJ 08543-0300
